2 FTSE 250 dividend stocks I’d buy and hold for 25 years

Royston Wild zeroes in on two terrific FTSE 250 (INDEXFTSE: MCX) income heroes that could make you richer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I spend a whole heap of time scouring the FTSE 250 for top-notch dividend shares to present to you. I always go in looking for stocks that investors will feel comfortable enough to buy and hold for a minimum of about five years, but there’s plenty out there whose bright futures extend far beyond such a timeframe.

Take Dechra Pharmaceuticals (LSE: DPH), for example. It’s fallen seriously out of favour in recent weeks amid concerns of rising competition in the animal healthcare segment, the company reporting in early September that “the veterinary market is seeing faster change than at any time in its history.”

Medicines demand for comfort and agricultural animals is heading through the roof, as underlined by Dechra reporting another double-digit-percentage revenues rise (at constant currencies) last month.

And I think that you can rely on the healthcare mammoth (which has spent a fortune to boost its geographical handprint and bolster its drugs pipeline through shrewd acquisitions) to keep impressing, despite the increased competition thanks to its fizzy M&A programme. Indeed, earlier this month, Dechra shelled out £37.8m on Laboratorios Vencofarma do Brasil, a specialist in developing products for livestock care in the fast-growing regions of South America.

It’s no surprise, to me at least, to see City brokers forecasting another hefty earnings rise in the current year, the 12 months to June 2019. A 12% increase is predicted and this leads to expectations that dividends will keep rising at an impressive rate, too — last year’s  payout of 25.5p per share is forecast to rise to 28.2p, resulting in a yield of 1.2%.

This reading, or Dechra’s forward P/E ratio of 26.5 times, may not suit all investors. In my opinion, though, the probability that it will keep delivering strong profits and dividend growth in the years — nay, decades — ahead still makes it a terrific share to stock up on today.

Out of fashion

The investment community has fallen out of love with Superdry (LSE: SDRY) too, on account of less-than-impressive financials last time out.

The fashion brand declared earlier in October that unusually hot weather in Europe and the US has dented demand for its autumn/winter clothing lines and that, as a result, full-year profits would take a hit to the tune of £10m.

Stock pickers have been a little too quick to cast Superdry adrift, though, as its long-term profits outlook remains exceptional. It is investing vast sums in its product lines to increase the range of highly-desirable items that it supplies, while it also continues to spend heavily on expanding its global store network and improving its increasingly-critical online channel.

Like Dechra, Superdry is no stranger to lifting the dividend at a solid pace, and although a 6% profits drop is forecast for the year to April 2019, the annual ordinary payout is predicted to grow to 33p per share from 31.2p last year, resulting in a chunky 4.1% yield. Further special dividends may also be in the offing given the rate at which Superdry is churning out cash.

At current prices Superdry trades on a forward P/E ratio of just 9.2 times, and this makes it too good to miss in my opinion.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Superdry. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

3 things investors should consider when building a £10k passive income

Ken Hall looks at three important considerations for investors looking to build a sizeable passive income for a better financial…

Read more »

Investing Articles

Here’s how much I need in a Stocks and Shares ISA to earn £50,000 of passive income a year

Is it realistic to one day generate £50k in dividend income from a Stocks and Shares ISA portfolio? This writer…

Read more »

Investing Articles

Up 124% in a year! But could the IAG share price still soar from here?

Christopher Ruane looks at why the IAG share price has more than doubled in the space of 12 months --…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

The genie’s out the bottle! After the US invests $500bn, are Warren Buffett’s AI fears warranted?

The new Trump administration's going full speed ahead with AI development, bringing to light fears Warren Buffett highlighted almost a…

Read more »

Investing Articles

The Burberry share price soars 15% after today’s results – is there more to come?

Harvey Jones is thrilled by the stellar performance of the Burberry share price this morning. This puts the lid on…

Read more »

Investing Articles

With £5,000 in UK shares, how much passive income could an investor expect?

A big question for UK investors is how much to pump into shares with the aim of achieving meaningful passive…

Read more »

Growth Shares

Greggs shares have tanked over the last 6 months and a broker says it’s time to sell

A City brokerage firm believes that Greggs shares could fall another 17% from here. Should investors give the stock a…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Have I called the BP share price completely wrong?

Harvey Jones has taken advantage of the slump in the BP share price to pile into this FTSE 100 oil…

Read more »